Chan W K, Heng W J, Tseng P, Balakrishnan V, Chan T K, Low C H
Singapore National Eye Center.
J Refract Surg. 1995 May-Jun;11(3 Suppl):S286-92. doi: 10.3928/1081-597X-19950502-21.
To conduct a prospective, nonrandomized clinical trial to assess the efficacy, stability and safety of the use of excimer laser photorefractive keratectomy (PRK) to correct myopia of greater than -6.00 diopters (D) in Singapore. Two hundred thirty-three eyes of 176 patients with a mean preoperative spherical equivalent refraction of -8.70 +/- 2.3 D (range, -5.75 D to -18.13 D) underwent PRK with a 193nm ArF excimer laser (ExciMed, Summit) for myopic corrections of between -6.20 D and -11.90 D. The first 66 of 233 eyes that reached at least 1 year of postoperative follow up are reported. One year postoperatively, the mean manifest spherical equivalent refraction was -1.50 D +/- 1.90 D (range -6.25 D to +3.25 D); 34% of eyes were within +/- 1.00 D of attempted correction; uncorrected visual acuity was 20/40 or better in 75% of eyes. No eyes lost two or more Snellen lines of spectacle corrected visual acuity. Central corneal haze was mild in 20% of eyes and moderate in 3% of eyes. Five eyes developed ocular hypertension that subsequently resolved with treatment. Excimer laser PRK is reasonably effective and safe in the treatment of -6.00 D to -12.00 D of myopia. However, it is less accurate than PRK in eyes with low to moderate myopia and is more likely to result in significant corneal haze.
在新加坡进行一项前瞻性、非随机临床试验，以评估准分子激光屈光性角膜切削术（PRK）矫正超过-6.00屈光度（D）近视的有效性、稳定性和安全性。176例患者的233只眼，术前平均等效球镜度为-8.70±2.3D（范围为-5.75D至-18.13D），接受了用193nm氟化氩准分子激光（ExciMed，Summit）进行的PRK治疗，近视矫正度数在-6.20D至-11.90D之间。报告了233只眼中首批随访至少1年的66只眼的情况。术后1年，平均显性感光等效球镜度为-1.50D±1.90D（范围为-6.25D至+3.25D）；34%的眼在预期矫正度数±1.00D范围内；75%的眼未矫正视力达到20/40或更好。没有眼的矫正视力损失两条或更多Snellen视力线。20%的眼角膜中央混浊轻度，3%的眼中度混浊。5只眼发生了高眼压，随后经治疗缓解。准分子激光PRK治疗-6.00D至-12.00D近视相当有效且安全。然而，与低至中度近视眼中的PRK相比，其准确性较低，且更有可能导致明显的角膜混浊。
